/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.27%
Natural Gas
+2.59%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.58%
VIX
N/A
Economic Calendar
EUR/USD
+0.27%
Natural Gas
+2.59%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.58%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Unemployment Claims: Steady; Philly Fed Survey: Manufacturing Strengthens
about 1 hour ago
Extended High Interest Rates Forecast to Impact Economic Stability
about 13 hours ago
Middle East Crisis: Geopolitics Remains a Downside Risk for the Global Economic and Credit Outlook
about 18 hours ago
Crude Inventories Rise By 2.7 Million Barrels, Exceeding Analyst Expectations
about 23 hours ago
UK Annual Inflation Rate Softens from 3.4% to 3.2% in March 2024
1 day ago
US Housing Market Faces March Decline
2 days ago
USD/JPY Forecast – US Dollar Continues to Look Strong Against The Yen
4 minutes ago
Crude Oil Price Forecast – Crude Continues to Be Noisy
10 minutes ago
Bitcoin Price Forecast – Bitcoin Continues to Attempt a Bounce
15 minutes ago
US Dollar (DXY) Index News: Strengthens Amid Treasury Yields Surge
17 minutes ago
Silver Price Forecast – Silver Continues to Consolidate
20 minutes ago
S&P 500 at 5,000 – Break or Hold?
44 minutes ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
JAZZ
profile
Jazz Pharmaceuticals plc
Follow
JAZZ
(
Nasdaq - US
)
Open
107.60
+0.50 (+0.47%)
in
:
usd
•
As of: Apr 18, 2024 09:45
UTC -4
Open
107.21
High
107.66
Low
107.21
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Jazz Pharmaceuticals plc
CEO
Bruce C. Cozadd
Headquarters
fifth floor, waterloo exchange, waterloo road
dublin, l2 d04, ireland
Auditor
KPMG
Employees
2,800
Share Holders
889
Website
www.jazzpharma.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
Jazz Pharmaceuticals plc
Statistics
Valuation Measures
Market Capitalization
2
6.78B
Enterprise Value
10.99B
Enterprise Value/EBITDA
(ttm)
9.02
Price to Earnings Ratio
(ttm)
6.96
Price to Book
(mrq)
1.83
Price to Sales
(ttm)
1.79
Price to Cash
(ytd)
3.91
Profitability
Gross Margin
(ttm)
88.57%
Operating Margin
(ttm)
28.72%
Profit Margin
(ttm)
11.39%
Return on Equity
(ttm)
31.27%
Return on Invested Capital
(ttm)
4.67%
Return on Assets
(ttm)
9.81%
Income Statement
Revenue
(ttm)
3.83B
Revenue Per Share
(ttm)
61.50
Gross Profit
(ttm)
3.40B
EBITDA
(ttm)
3
1.22B
Net Income Avi to Common
(ttm)
439.71M
Diluted EPS
(ttm)
6.12
Share Statistics
Beta (5Y Monthly)
0.59
52-Week Change
-25.05%
S&P500 52-Week Change
21.16%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
62.35M
Dividend Yield
0.00%
Float
4
60.23M
%
Held by Insiders
4.40%
%
Held by Institutions
89.14%
Balance Sheet
Total Cash
(mrq)
1.63B
Total Cash Per Share
(mrq)
26.09
Total Debt
(mrq)
5.71B
Total Debt/Equity
(mrq)
152.88%
Current Ratio
(mrq)
2.24%
Quick Ratio
(mrq)
1.85%
Book Value Per Share
(mrq)
60.03
Cash Flow
Operating Cash Flow Per Share
(ytd)
15.15
Free Cash Flow
(ytd)
1.07B
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker